Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer

Activating KRAS mutations are found in over 90% of pancreatic ductal adenocarcinomas (PDACs), yet KRAS has remained a difficult target to inhibit pharmacologically. Here, we demonstrate, using several human and mouse models of PDACs, rapid acquisition of tumor resistance in response to targeting KRA...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Wells S., McDonald, Paul C., Nemirovsky, Oksana, Awrey, Shannon, Chafe, Shawn C., Schaeffer, David F., Li, Jinyang, Renouf, Daniel J., Stanger, Ben Z., Dedhar, Shoukat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691443/
https://www.ncbi.nlm.nih.gov/pubmed/33294856
http://dx.doi.org/10.1016/j.xcrm.2020.100131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691443/
https://www.ncbi.nlm.nih.gov/pubmed/33294856
http://dx.doi.org/10.1016/j.xcrm.2020.100131

Ejemplares similares